BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20881488)

  • 1. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents.
    Perry JR
    Curr Opin Neurol; 2010 Dec; 23(6):592-6. PubMed ID: 20881488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thrombosis in patients with high-grade glioma.
    Taillibert S; Taillandier L; Le Rhun E
    Curr Opin Oncol; 2015 Nov; 27(6):516-21. PubMed ID: 26447877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
    van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
    Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary venous thromboembolism prophylaxis in ambulatory cancer patients.
    Aikens GB; Rivey MP; Hansen CJ
    Ann Pharmacother; 2013 Feb; 47(2):198-209. PubMed ID: 23386067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: angiogenesis and antiangiogenic therapy for malignant gliomas.
    Kepes JJ
    Brain Tumor Pathol; 2005; 22(1):51. PubMed ID: 18095105
    [No Abstract]   [Full Text] [Related]  

  • 6. Subcutaneous heparin for prophylaxis of venous thromboembolism in deep brain stimulation surgery: evidence from a decision analysis.
    Bauman JA; Church E; Halpern CH; Danish SF; Zaghloul KA; Jaggi JL; Stein SC; Baltuch GH
    Neurosurgery; 2009 Aug; 65(2):276-80; discussion 280. PubMed ID: 19625905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and old anticoagulants in cancer.
    Verso M; Agnelli G
    Thromb Res; 2012 Apr; 129 Suppl 1():S101-5. PubMed ID: 22682118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.
    Norden AD; Bartolomeo J; Tanaka S; Drappatz J; Ciampa AS; Doherty LM; Lafrankie DC; Ruland S; Quant EC; Beroukhim R; Wen PY
    J Neurooncol; 2012 Jan; 106(1):121-5. PubMed ID: 21706358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombosis in brain tumors.
    Jo JT; Schiff D; Perry JR
    Semin Thromb Hemost; 2014 Apr; 40(3):325-31. PubMed ID: 24599439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
    Soto-Cárdenas MJ; Pelayo-García G; Rodríguez-Camacho A; Segura-Fernández E; Mogollo-Galván A; Giron-Gonzalez JA
    Palliat Med; 2008 Dec; 22(8):965-8. PubMed ID: 18952751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism: a clinical review.
    Osinbowale O; Ali L; Chi YW
    Postgrad Med; 2010 Mar; 122(2):54-65. PubMed ID: 20203456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboprophylaxis in non-surgical cancer patients.
    Cohen AT; Gurwith MM; Dobromirski M
    Thromb Res; 2012 Apr; 129 Suppl 1():S137-45. PubMed ID: 22682125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of angiogenesis and invasion in malignant gliomas.
    Chi A; Norden AD; Wen PY
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1537-60. PubMed ID: 18020923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: a case series study.
    Vitale FV; Rotondo S; Sessa E; Parisi A; Giaimo V; D'Angelo A; Antonelli G; Romeo P; Ferraù F
    J Oncol Pharm Pract; 2012 Mar; 18(1):10-6. PubMed ID: 21228085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.
    de Jong PG; Coppens M; Middeldorp S
    Br J Haematol; 2012 Aug; 158(4):433-41. PubMed ID: 22734929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Optimal duration of anticoagulation of venous thromboembolism].
    Savina EN; Couturaud F
    J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer.
    Tran QN
    Am J Hosp Palliat Care; 2010 Sep; 27(6):416-9. PubMed ID: 20197558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    Agnelli G; George DJ; Kakkar AK; Fisher W; Lassen MR; Mismetti P; Mouret P; Chaudhari U; Lawson F; Turpie AG;
    N Engl J Med; 2012 Feb; 366(7):601-9. PubMed ID: 22335737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of venous thromboembolism in patients with cancer.
    Prandoni P
    Intern Emerg Med; 2010 Oct; 5 Suppl 1():S27-30. PubMed ID: 20865471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options.
    Ay C; Pabinger I
    Hamostaseologie; 2012; 32(2):139-44. PubMed ID: 21822525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.